Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Avalyn Pharma Inc. Common Stock (AVLN)
Boston, MA, US
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Metric |
Dec 2025 actual |
Dec 2026 1 EPS Ana. |
Dec 2027 2 EPS Ana. |
Dec 2028 3 EPS Ana. |
Dec 2029 1 EPS Ana. |
Dec 2030 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
—
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBITDA |
-91.25M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-91.29M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-85.20M
est: -190.67M (+55.3%)
|
-112.79M
-112.79M – -112.79M
+40.8% YoY
|
-96.79M
-96.79M – -96.79M
+14.2% YoY
|
-146.53M
-172.29M – -72.58M
-51.4% YoY
|
-153.66M
-153.66M – -153.66M
-4.9% YoY
|
-156.38M
-156.38M – -156.38M
-1.8% YoY
|
| SGA |
14.68M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-2.04
est: -4.56 (+55.3%)
|
-2.70
-2.70 – -2.70
+40.8% YoY
|
-2.32
-2.32 – -2.32
+14.2% YoY
|
-2.82
-4.12 – -1.74
-22.0% YoY
|
-3.68
-3.68 – -3.68
-30.2% YoY
|
-3.74
-3.74 – -3.74
-1.8% YoY
|
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | T. Rowe Price Small-Mid Cap ETF TMSL | 0.06% | 1.79M | 0.55% |
| 2 | T. Rowe Price Innovation Leaders ETF TNXT | 0.06% | 10.0K | 0.49% |
| 3 | Invesco Russell 2000 Dynamic Multifactor ETF OMFS | 0.02% | 68.0K | 0.39% |
| 4 | iShares Russell 2000 Growth ETF IWO | 0.02% | 3.12M | 0.24% |
| 5 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.02% | 482.0K | 0.30% |
| 6 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.02% | 48.9K | 0.25% |
| 7 | Global X - Russell 2000 ETF RSSL | 0.02% | 223.7K | 0.08% |
| 8 | iShares Russell 2000 BuyWrite ETF IWMW | 0.02% | 8.5K | 0.39% |
| 9 | iShares Russell 2000 ETF IWM | 0.01% | 12.46M | 0.19% |
| 10 | iShares U.S. Small Cap Index ETF (CAD-Hedged) XSU.TO | 0.01% | 81.4K | 0.36% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AVLN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
